Updates in the Treatment Landscape of AML
Eunice Wang, MD, discusses the new treatment era for patients with acute myeloid leukemia after the approval of 3 new treatment regimens at the end of 2018.
Eunice Wang, MD, chief of the leukemia service at the Roswell Park Comprehensive Cancer Center, discusses the new era of treatment for patients with acute myeloid leukemia (AML) afterthe approval of 3 new treatment regimensat the end of 2018.
With these approvals, physicians are questioning how necessary the standard backbone chemotherapy low-dose cytarabine and anthracycline-based treatments are; these agents have been the standard since the 1970s for younger and fitter patients.
For the last few years, physicians have been using low-dose hypomethylating agents for older patients. In the last year, there has been a breakthrough in terms of combination therapy with low-dose chemotherapy and oral agents.
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
January 24th 2025The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia or myelodysplastic syndromes has been approved by the FDA.
Read More
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
